gms | German Medical Science

48th Meeting of the Particle Therapy Co-Operative Group

Particle Therapy Co-Operative Group (PTCOG)

28.09. - 03.10.2009, Heidelberg

Monte Carlo calculations of organ doses due to secondary neutrons during ophthalmologic proton therapy treatments

Meeting Abstract

  • F. Martinetti - Département de la Radioprotection de l'Homme, Institut de Radioprotection et de Sûreté Nucléaire, Fontenay aux roses, France
  • L. Donadille - Département de la Radioprotection de l'Homme, Institut de Radioprotection et de Sûreté Nucléaire, Fontenay aux roses, France
  • D. Sabine - Institut Curie - Centre de Protonthérapie d'Orsay, Orsay, France
  • A. De Oliveira - Institut Curie - Centre de Protonthérapie d'Orsay, Orsay, France
  • I. Ribaux - Service de Dosimétrie, Institut de Physique Nucléaire, Orsay, France
  • I. Robbes - Département de la Radioprotection de l'Homme, Institut de Radioprotection et de Sûreté Nucléaire, Fontenay aux roses, France
  • J. Hérault - Cyclotron Biomédical, Centre Antoine Lacassagne, Nice, France

PTCOG 48. Meeting of the Particle Therapy Co-Operative Group. Heidelberg, 28.09.-03.10.2009. Düsseldorf: German Medical Science GMS Publishing House; 2009. Doc09ptcog131

DOI: 10.3205/09ptcog131, URN: urn:nbn:de:0183-09ptcog1312

Published: September 24, 2009

© 2009 Martinetti et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

The 73 MeV proton beam line dedicated to ophthalmologic treatments at the ICPO was modelled at IRSN with the MCNPX Monte Carlo code. The ability of the model to adequately reproduce the measured proton absorbed dose distributions in a water phantom was shown in a previous work [1]. Three experimental validations of the model, relating secondary radiations produced during treatment, were performed. They concerned (i) the neutron ambient dose equivalents in the therapy room (ii) neutron spectra and (iii) neutron and photon absorbed doses inside an anthropomorphic phantom. The model was then used to estimate the secondary doses received by the organs of the patient. Absorbed doses and equivalent doses in organs due to secondary neutrons were estimated using a mathematical phantom. The neutron spectra were also calculated in the organs.

For the validation parts measurements were made under clinical treatment conditions. First, the ambient dose equivalents due to neutrons were measured at several points around the isocentre using neutron probes and tissue equivalent proportional counters. Second, the neutron spectrometry was performed at 2 points with a Bonner spheres system specifically developed for high energy neutron fields. Third, the doses deposited by secondary neutrons and photons were measured at 8 points inside a Rando-Alderson phantom placed to reproduce an ophthalmologic treatment. Thermoluminescent detectors (7LiF) and track etched detector (CR-39) were used to estimate the photon and neutron dose components, respectively. For the estimation of organ doses, a mathematical phantom was implemented and neutron absorbed and equivalent doses were calculated in the 14 organs defined in the ICRP Publication #60, as well as in the non-treated eye.

For the 3 sets of validation measurements a good agreement between experimental and calculated data is obtained. For a typical ophthalmologic treatment (60 Gy eq. 60Co) neutron equivalent doses range from 0,65 mSv to around 13,5 mSv for the ovaries and the non-treated eye, respectively. Results relating to the validation process of the model will be discussed as well as the secondary organs doses which will be compared to available data from the literature.


References

1.
Martinetti F, Donadille L, Delacroix S, Nauraye C, De Oliveira A, Hérault J, Clairand I. Monte Carlo Modelling of a proton therapy beam-line dedicated to ophthalmologic treatments (at press). Nuclear Technology.